Finance entity
AbbVie is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Each story carries 5.5 original sources on average, compared with 3.6 for the broader beat in this window. At 6.5, the average consequence score sits above the same-window beat average of 6.1.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
AbbVie is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Each story carries 5.5 original sources on average, compared with 3.6 for the broader beat in this window. At 6.5, the average consequence score sits above the same-window beat average of 6.1. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. This profile follows 2 Finance stories mentioning Genmab A/S across the period from February 17, 2026 to February 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 283 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Genmab A/S. Shared-story counts are live from our verified record — not editorial picks.
Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
The equity markets are navigating a complex landscape of 'sell-the-news' reactions and extreme biotech volatility following a series of clinical and financial updates. While Compass Pathways surged on positive trial results, Ocular Therapeutix and Genmab faced significant selling pressure despite reaching key milestones.
Genmab A/S is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
